PMID: 3757157Jan 1, 1986Paper

Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion

Cancer Chemotherapy and Pharmacology
N S TchekmedyianJ Aisner

Abstract

A total of 14 patients, 7 male and 7 female, received in all 21 evaluable courses of cyclophosphamide administered by 5-day continuous infusion. Cyclophosphamide doses were escalated from 300 to 400 mg/m2 per day for 5 days and repeated every 21-28 days. The patient population had a median age of 55 years (range 38-76) and a median Karnofsky performance status of 80 (range 60-100). Only 1 patient had not received prior therapy; 5 patients had received only prior chemotherapy, 1 had received only prior radiotherapy, and 7 had received both. Tumor types were gastric (1), lung (2), colon (4), urethral adenocarcinoma (1), cervical (2), chondrosarcoma (1), melanoma (1), uterine leiomyosarcoma (1), and pancreatic (1). The dose-limiting toxicity was granulocytopenia, with median WBC nadir of 1700/microliter (range 100-4800) in 8 heavily pretreated patients treated at 350 mg/m2 per day for 5 days. One patient without heavy prior treatment received two courses at 400 mg/m2 and had WBC nadirs of 800/microliter and 600/microliter. WBC nadirs occurred between days 9 and 21 (median 14). Drug-induced thrombocytopenia occurred in only one patient (350 mg/m2 per day, nadir 85,000/microliter). Neither hyponatremia nor symptomatic hypo-osmolalit...Continue Reading

References

Jun 1, 1979·Annals of Internal Medicine·J M Bennett, S D Reich
Sep 1, 1979·Clinical Pharmacokinetics·L B Grochow, M Colvin
Jan 1, 1979·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M D'IncalciM Salmona
Sep 1, 1979·British Journal of Clinical Pharmacology·F D JumaJ R Trounce
Dec 1, 1979·Computer Programs in Biomedicine·G D Knott
Jan 1, 1978·Cancer Chemotherapy and Pharmacology·F D JumaI D Bradbrook
Aug 1, 1974·Acta Pharmacologica Et Toxicologica·H T MouridsenL Skovsted
Nov 1, 1971·British Journal of Pharmacology·J L CohenW J Jusko
Sep 1, 1983·Cancer Treatment Reviews·R Stuart-HarrisE Wiltshaw
Jun 1, 1983·American Journal of Clinical Oncology·A Y Bedikian, G P Bodey
Feb 1, 1982·Annals of Internal Medicine·S S LeghaE J Freireich
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·J AisnerP H Wiernik
Sep 1, 1980·Cancer Treatment Reviews·G P BodeyM Valdivieso

❮ Previous
Next ❯

Citations

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·M J TassoJ R Idle
Oct 20, 2005·Clinical Pharmacokinetics·Milly E de JongeJos H Beijnen
Jan 1, 1989·Biomaterials, Artificial Cells, and Artificial Organs·P D NguyenB M Fung
Sep 30, 1998·British Journal of Haematology·V Santini, P R Ferrini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.